Nintedanib Accordpharma

Nintedanib, the active ingredient in Nintedanib Accordpharma, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and as part of combination therapy for non‑small cell lung cancer.

GNH USA supplies Nintedanib Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib acts on fibrotic and oncogenic pathways, providing therapeutic benefit in several pulmonary and oncologic conditions.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delays worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with other anticancer agents.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Decreased appetite - Vomiting - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Hepatic failure - Severe bleeding events - Cardiovascular complications (e.g., myocardial infarction) - Gastrointestinal perforation - Severe infections - Pneumothorax

When prescribing Nintedanib, clinicians should consider several safety precautions.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: perform baseline and periodic liver‑function tests. - Bleeding risk: avoid concomitant use of strong anticoagulants unless benefits outweigh risks. - Pregnancy: use only if potential benefit justifies potential fetal risk. - Cardiovascular disease: assess baseline risk and monitor for cardiac events. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Nintedanib can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding. - High‑dose aspirin or other antiplatelet agents: elevated bleeding potential.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - P‑gp inhibitors (e.g., verapamil): could raise plasma concentrations. - Diuretics: monitor for dehydration and renal function.